Coker S J, Parratt J R
Br J Pharmacol. 1985 Sep;86(1):259-64. doi: 10.1111/j.1476-5381.1985.tb09457.x.
The effects of the thromboxane antagonist AH23848 (1 mg kg-1 i.v.) were examined in anaesthetized greyhounds prepared for occlusion of the left anterior descending coronary artery with subsequent reperfusion after 40 min of myocardial ischaemia. Pretreatment with AH23848 30 min before coronary artery occlusion reduced the number of ischaemia-induced extrasystoles to 339 +/- 111 compared with 736 +/- 153 in the control group. The incidence of ventricular fibrillation following reperfusion was also markedly reduced; 25% compared with 88% in the controls. Late intervention with AH23848, 25 min after the onset of myocardial ischaemia did not significantly alter the incidence of reperfusion-induced ventricular fibrillation; 70% of the control group died and 60% of those that received AH23848. The ischaemia-induced release of thromboxane A2 and prostacyclin was not altered by pretreatment with AH23848. The results suggest that blockade of thromboxane receptors before myocardial ischaemia is an effective antiarrhythmic strategy in this model.
在为左冠状动脉前降支闭塞及随后心肌缺血40分钟后再灌注而准备的麻醉灵缇犬中,研究了血栓素拮抗剂AH23848(静脉注射1毫克/千克)的作用。冠状动脉闭塞前30分钟用AH23848预处理,使缺血诱导的早搏数量减少至339±111次,而对照组为736±153次。再灌注后室颤的发生率也显著降低;为25%,而对照组为88%。在心肌缺血开始25分钟后用AH23848进行晚期干预,并未显著改变再灌注诱导的室颤发生率;对照组70%的犬死亡,接受AH23848的犬中有60%死亡。AH23848预处理并未改变缺血诱导的血栓素A2和前列环素的释放。结果表明,在该模型中,心肌缺血前阻断血栓素受体是一种有效的抗心律失常策略。